950results about How to "Inhibit progress" patented technology

The present invention teaches a method and apparatus for physiological modulation, including neural and gastrointestinal modulation, for the purposes of treating several disorders, including obesity, depression, epilepsy, and diabetes. This includes chronically implanted neural and neuromuscular modulators, used to modulate the afferent neurons of the sympathetic nervous system to induce satiety. Furthermore, this includes neuromuscular stimulation of the stomach to effect baseline and intermittent smooth muscle contraction to increase gastric intraluminal pressure, which induces satiety, and stimulate sympathetic afferent fibers, including those in the sympathetic trunk, splanchnic nerves, and greater curvature of the stomach, to augment the perception of satiety.

The present invention relates to antibodies or fragments thereof that specifically bind FcgammaRIIB, particularly human FcgammaRIIB, with greater affinity than said antibodies or fragments thereof bind FcgammaRIIA, particularly human FcgammaRIIA. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.

A light therapy system provides for self-alignment or positioning with respect to a joint of a subject. The light therapy system can provide light therapy to a body part of a subject. The therapy system has a main body configured to be placed adjacent a target site and an activatable light emitting system is coupled to the main body. The light emitting system is capable of delivering a therapeutic amount of light energy to the target site when the main body is placed adjacent the target site.

The present invention teaches a method and apparatus for user control and operation of physiological modulation, including neural and gastrointestinal modulation, for the purposes of treating several disorders, including obesity, metabolic disease, and other conditions. This includes programming of neuromodulatory signal for the modulation of autonomic neural and neuromuscular modulators, used to modulate tissues, including the afferent neurons of the sympathetic nervous system to induce satiety and efferent neurons to modulate metabolism. The apparatus and methods include a conformal neuromodulator array which facilitates minimally invasive placement of neuromodulators in communication with target tissues.

Therapeutic agent delivery formulations for the sustained release of therapeutic agents from a Port Delivery System (PDS) implant is described in this application.

Contact lenses incorporating an array of non-coaxial lenslets with add power that create non-coaxial myopic defocus within the optic zone of the lens may be utilized to prevent and/or slow myopia progression. The positive, non-coaxial lenslets cover about twenty to eighty percent of the central pupil area to deliver positive foci of light in front of the retina to slow the rate of myopia progression.

The present invention teaches methods and apparatus for user control and operation of physiological modulation, including neural and gastrointestinal modulation, for the purposes of treating several disorders, including obesity. This includes programming of neuromodulatory signal for the modulation of autonomic neural and neuromuscular modulators, used to modulate tissues, including the afferent neurons of the sympathetic nervous system to induce satiety and efferent neurons to modulate metabolism.

The invention relates to methods and compounds for treating or preventing cancer. Methods for treating or preventing cancer, for inhibiting tumor growth, reducing tumor volume, inhibiting tumor progression, inhibiting metastasis, and improving survival are provided herein.

Provided herein are influenza hemagglutinin stem domain polypeptides, compositions comprising the same, vaccines comprising the same and methods of their use.

PCT No. PCT/US96/08992 Sec. 371 Date Jun. 5, 1996 Sec. 102(e) Date Jun. 5, 1996 PCT Filed Jun. 5, 1996Disclosed are an isolated antibody or antibody fragment that selectively binds a polypeptide encoded by Cytokine Response gene 2 (CR2), and in particular, selectively binds to a first polypeptide having the sequence of residues 1-60 of SEQ. ID No: 4. Also disclosed is a composition containing the antibody or antibody fragment and a diluent or carrier. Also disclosed are methods, using the present antibody or antibody fragment, of isolating or purifying a peptide comprising an amino acid sequence of residues 1-60 of SEQ. ID No: 4 or an antibody binding fragment thereof that is at least 10 to 30 amino acids long, or a fusion protein comprising any of these.

Methods of treating complement-mediated ocular disorders by administering agents that inhibit a subject's complement component in an amount sufficient to treat the ocular disorder wherein, in a selected embodiment, said agent is an anti-complement aptamer that, in a preferred embodiment, is an anti-C5 aptamer.

Variant immunoglobulins with one or more amino acid modifications in the Fc region that have increased in vivo half-lives, and methods of using the same are provided.

The invention relates to sustained release implants and to methods for treating eyes, particularly the eyes of mammals having eye disorders or diseases. By using the implants and methods described herein, the delivery of the one or more bioactive agents can be localized at a desired treatment site, particularly the choroid and the retina.

An artificial cornea comprising an optical element made of an optically transparent material, having a front surface and a posterior surface, and a skirt provided so as to support with surrounding at least a part of the optical element, characterized in that the skirt is provided with a flange on its side facing the interior of eyes during implantation of the artificial cornea and the flange radially protrudes outward from the skirt. The artificial cornea can be well compatible with ocular tissue, prevent leakage of intraocular aqueous humor and intraocular invasion of bacteria, reduce stimulation on palpebral conjunctiva and further, inhibit progression of the down growth, and which has no possibility of reduction in transparency of the optical element due to the down growth as well as detachment and extrusion from the implanted state.

The invention provides human regulatory molecules and polynucleotides (collectively designated HRM) which identify and encode them. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention further provides methods for diagnosing, preventing, and treating disorders associated with expression of human regulatory molecules.

Disclosed herein are compositions and methods used to modulate a NH₂-terminal Jun Kinase activity. These compositions and methods can be employed to regulate metabolic disorders associated with, for example, insulin such as diabetes. The reduction in NH₂-terminal Jun Kinase activity can lead to the reduction in weight and improve insulin sensitivity.

The invention provides human extracellular adhesive proteins (EXADH) and polynucleotides which identify and encode EXADH. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of EXADH.